Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

British Journal of Haematology

Volumn 143, Issue 3, 2008, Pages 355-360

  Pro, Barbara ^a,e   Leber, Brian ^b   Smith, Mitchell ^c   Fayad, Luis ^a   Romaguera, Jorge ^a   Hagemeister, Fredrick ^a   Rodriguez, Alma ^a   McLaughlin, Peter ^a   Samaniego, Felipe ^a   Zwiebel, James ^d   Lopez, Adriana ^a   Kwak, Larry ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Non Hodgkin lymphoma; Oblimersen sodium; Recurrent B cell NHL; Rituximab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; OBLIMERSEN; PROTEIN BCL 2; PURINE DERIVATIVE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CYTOKINE RELEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; RECURRENCE; SURVIVAL ANALYSIS; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 54049145194     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07353.x     Document Type: Article

References (14)

1. Auer, R.L., Corbo, M., Fegan, C.D., Frankel, S.R. Cotter, F.E. (2001) Bcl-2 antisense (Genasense) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells. Blood, 98, 808a.
2. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
3. Cotter, F.E., Auer, R., Corbo, M., McElwaine, S. Frankel, S.R. (2003) Oblimersen sodium (G3139) sensitizes malignant B-cells to alemtuzumab induced apoptosis. Journal of Clinical Oncology, 22, 227a.
4. Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. Levy, R. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 3135 3143.
5. Gascoyne, R.D., Adomat, S.A., Krajewski, S., Krajewska, M., Horsman, D.E., Tolcher, A.W., O'Reilly, S.E., Hoskins, P., Coldman, A.J., Reed, J.C. Connors, J.M. (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90, 244 251.
6. Hermine, O., Haioun, C., Lepage, E., d'Agay, M.F., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J.P., Diebold, J., Reyas, F. Gaulard, P. (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 87, 265 272.
7. Klasa, R.J., Bally, M.B., Ng, R., Goldie, J.H., Gascoyne, R.D. Wong, F.M. (2000) Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clinical Cancer Research, 6, 2492 2500.
8. Leonard, J.P., Coleman, M., Vose, J., Hainsworth, J.D., Piro, L., Saleh, M., Berstein, S., Ferero-Torres, A., Frankel, S.R. Itri, L.M. (2003a) Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proceedings of American Society of Clinical Oncology, 22, 566.
9. Leonard, J.P., Hainsworth, J., Bernstein, S., Ferero-Torres, A., Vose, J., Piro, L., Saleh, M., Coleman, M., Frankel, S., Smith, S. Itri, L. (2003b) Genasense (oblimersen sodium, G3139) is active and well tolerated both alone and with R-CHOP in mantle cell lymphoma (MCL). Blood, 102, 143a.
10. O'Brien, S.M., Cunningham, C.C., Golenkov, A.K., Turkina, A.G., Novick, S.C. Rai, K.R. (2005) Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 7697 7702.
11. O'Brien, S., Moore, J.O., Boyd, T.E., Larratt, L.M., Skotnicki, A., Koziner, B., Chanan-Khan, A.A., Seymour, J.F., Bociek, R.G., Pavletic, S. Rai, K.R. (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 1114 1120.
12. Reed, J.C. (1999) Dysregulation of apoptosis in cancer. Journal of Clinical Oncology, 17, 2941 2953.
13. Smith, M.R., Jin, F. Joshi, I. (2004) Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Molecular Cancer Therapeutics, 3, 1693 1699.
14. Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., Raynaud, F., di Stefano, F. Cotter, F.E. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 18, 1812 1823.